Anti-β7 integrin treatment impedes the recruitment on non-classical monocytes to the gut and delays macrophage-mediated intestinal wound healing.

Katrin SommerKarin HeidbrederLucas KreissMark DeddenEva-Maria PaapMaximilian WiendlEmily BeckerRaja AtreyaTanja M MüllerImke AtreyaMaximilian WaldnerSebastian SchürmannOliver FriedrichMarkus F NeurathSebastian Zundler

Published in: Clinical and translational medicine (2023)

Combined blockade of αEβ7 and α4β7 with etrolizumab seems to exceed the effect of anti-α4β7 treatment on intestinal wound healing, which might help to inform further investigations to understand the recent observations in the etrolizumab phase III trial program.

Keyphrases

phase iii
wound healing
clinical trial
open label
phase ii
adipose tissue
randomized controlled trial
study protocol
combination therapy
replacement therapy
dendritic cells
smoking cessation